Master Class: Managing Toxicities with TKIs in combination with Checkpoint Inhibitors in Endometrial Cancer-Master Class: Managing Toxicities with TKIs in combination with Checkpoint Inhibitors in Endometrial Cancer

Master Class: Managing Toxicities with TKIs in combination with Checkpoint Inhibitors in Endometrial Cancer

Video Transcription

Video Summary

The video is a master class on managing toxicities with TKIs in combination with checkpoint inhibitors in endometrial cancer. The presenter discusses the recent approval of the combination of lenvatinib and pembrolizumab in advanced recurrent endometrial cancer. They emphasize that the toxicity management strategies discussed are applicable to other agents in the VEGF TKI and checkpoint inhibitor classes. The presenter also provides housekeeping items such as the availability of the recording of the webinar on the IGCS education portal, and encourages viewers to submit questions. <br /><br />The presenter highlights the rising incidence and mortality rates of endometrial cancer worldwide, as well as the lack of major treatment advances in the disease. They discuss the results of the Phase 1b2 and Phase 3 clinical trials that led to the approval of lenvatinib plus pembrolizumab for advanced endometrial cancer. The most common adverse events associated with the combination therapy are hypertension, hypothyroidism, diarrhea, nausea, and decreased appetite. The presenter provides recommendations for managing these toxicities, including regular monitoring of blood pressure, use of antidiarrheal agents, and initiation of thyroid replacement therapy for hypothyroidism. They also discuss dose modifications and possible referral to specialists for severe adverse reactions.<br /><br />Overall, the video provides insights into the management of toxicities associated with the combination of lenvatinib and pembrolizumab in endometrial cancer. The presenter emphasizes the need for early detection and proactive management of adverse reactions to optimize patient care. The video also provides additional resources and highlights the upcoming IGCS annual global meeting.

Keywords

toxicities

endometrial cancer

lenvatinib

pembrolizumab

toxicity management

Phase 3 clinical trials

adverse events